Mass Spectrometry In Clinical Diagnostics: Market Trends And Future Prospects

By Author: Markets and Markets
Total Articles: 161
Comment this article

Mass Spectrometry Market in terms of revenue was estimated to be worth $5.4 billion in 2023 and is poised to reach $7.8 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety, growing focus on the quality of food products, increase in crude and shale gas production, and growing government initiatives for pollution control and environmental testing are high growth prospects for the mass spectrometry market during the forecast period.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437

Mass Spectrometry Key Market Players:

The mass spectrometry business is very competitive, with both established companies and newcomers competing for the same market share. As of 2022, the key players operating in the global mass spectrometry market are SCIEX AB (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan) and Bruker ...
... Corporation (US) among others.

Instruments segment to register significant growth rate over the forecast period of 2023-2028

Based on the product, the mass spectrometry is segmented into instrument and software & services. Instruments segment to register significant growth rate over the forecast period of 2023-2028. Advantages offered by instruments, such as rapid and high-resolution testing abilities with more accurate and precise results, are increasing its adoption. Consequently, the demand for mass spectrometry devices for high throughput screening is also growing. The instrument segment is further divided into hybrid mass spectrometry, single mass spectrometry and other technologies.

LC-MS segment accounted for the largest share of the mass spectrometry in 2023-2028

Based on sample preparation technique, the mass spectrometry is segmented into GC-MS, LC-MS, ICP-MS, and others. The LC-MS segment is estimated to hold the largest market share of the mass spectrometry market during the forecast period. The large share of this segment can be attributed to its ability to identify and measure a broader range of compounds with minimal sample preparation. LC-MS can identify a broader range of compounds. LC-MS is applied in many industries such as pharmaceuticals, biopharmaceuticals, forensic, industrial, food and environmental sector. For clinical research, the analysis of drugs, vitamins and minerals in whole blood, plasma, serum and urine is conducted routinely using LCMS. It is a more sensitive instrument.

OMICS research segment accounted for the largest share of the mass spectrometry in 2023-2028

Based on application, the mass spectrometry is segmented into OMICS research, drug discovery, environmental testing, food testing, pharma-biopharma manufacturing, clinical diagnostics, applied industries, and other applications. The OMICS research segment is estimated to hold the largest market share of the mass spectrometry market during the forecast period. The large share of this segment can be attributed to the increasing application of omics technology in diagnostics & biomarker identification and the increasing R&D expenditure and government funding for proteomics are expected to drive the market for this segment.

Pharmaceutical companies’ segment to register for the highest growth rate of the mass spectrometry in 2023-2028

The major end users in the mass spectrometry market are pharmaceutical companies, biotechnology companies, research labs & academic institutes, environmental testing labs, F&B industry, forensic labs, petrochemical industry and other end users. Pharmaceutical companies are expected to dominate the market during the forecast period. The availability of government and corporate funding for pharmaceutical research, growth of the pharmaceutical industry, and the presence of stringent regulatory guidelines for drug development and safety are some of the key factors driving the growth of this segment during the forecast period.

Asia Pacific to register a significant growth in the market during the forecast period

In 2023, Asia Pacific is expected to register a significant growth in the market during the forecast period. Asia Pacific comprises the China, Japan, India, South Korea, Australia, ASEAN Region, rest of APAC. Factors such as the significant funding for mass spectrometry and environmental monitoring regulations are driving the growth of the Asia Pacific mass spectrometry market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=437

Mass Spectrometry Market Dynamics:

Drivers:
1. Technological advancements in mass spectrometers
2. Government initiatives for pollution control and environmental testing
3. Increasing spending on pharmaceutical R&D
4. Government regulations on drug safety
5. Growing focus on quality of food products
6. Increase in crude and shale gas production
Restraints:
1. Premium Product Pricing
Opportunities:
1. Growing opportunities in emerging markets
Challenges:
1. Dearth of Skilled Professionals

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=437

Recent Developments:

• In January 2022, Thermo Fisher and Symphogen extended their collaborative partnership with aim to deliver workflows for simplified characterization and quality monitoring of complex therapeutic proteins using the Thermo Scientific Q Exactive Plus Orbitrap LC-MS/MS system.
• In February 2023, SCIEX announced collaboration with HighRes Biosolutions to bring customizable automation solutions powered by Cellario software, which would add automation benefits to the Echo MS system.
• In February 2022, Waters Corporation acquired Charge Detection Mass Spectrometry technology assets and intellectual property rights of Megadalton Solutions, Inc., to broaden its application in Cell and Gene Therapy.
• In September 2022, Agilent Technologies partnered with MOBILion Systems for ion mobility separation technology called Structures for Lossless Ion Manipulation (SLIM) on its Q-TOF mass spectrometers.

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/mass-spectrometry-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/mass-spectrometry-market.asp